SCHEDULE 13G/A: Janus Henderson Group Discloses 11.3% Stake in Benitec Biopharma Inc.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 11.3% of Benitec Biopharma Inc.'s common stock as of December 31, 2024.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, along with its indirect subsidiaries, reported beneficial ownership of 2,616,427 shares of Benitec Biopharma Inc. common stock.
• This represents 11.3% of Benitec Biopharma Inc.'s common stock.
• One of its subsidiaries, Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based investment company, beneficially owns 1,984,639 shares, representing 8.6% of the class.
• The shares are held with shared voting and shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual regulatory filing (Schedule 13G) reporting beneficial ownership, which does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in the biopharma sector, with a major investment group like Janus Henderson maintaining a significant stake in Benitec Biopharma Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling confidence from a major investment firm.

Key Dates

Keywords

Benitec Biopharma Inc., Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Biopharma, Investment Adviser, Institutional Investor